Obesity affects more than 40% of U.S. adults, disproportionately concentrated in specific populations — but access to the medications most effective at treating it is distributed in something close to the opposite pattern. The disparities literature on GLP-1 access spans insurance coverage, geography, race, age, and adherence, and several 2026 data points quantify the gap directly.
Insurance coverage: a shrinking, unevenly distributed benefit
As of January 2026, only 13 state Medicaid programs cover GLP-1 medications for obesity treatment under fee-for-service — down from 16 states reported as of October 2025, a net reduction rather than the expansion the broader policy conversation might suggest.[1] Four states have eliminated coverage entirely as of January 2026, including Pennsylvania and California, whose Medi-Cal program ended weight-loss-only GLP-1 coverage effective January 1, 2026 regardless of manufacturer price reductions.[2] Fewer than one-third of private insurers cover GLP-1s for weight loss specifically, even though coverage for the same medications used to treat type 2 diabetes is considerably more common.
Geography compounds the problem
States with the highest obesity rates — Mississippi, West Virginia, and Louisiana, all above 40% adult obesity prevalence — also rank near the bottom nationally for per capita income, pushing the income burden required to maintain continuous GLP-1 treatment above 12% of annual income in an analysis of state-level affordability.[3] Even after recent price reductions, Americans still pay two to four times more for GLP-1 medications than patients in Europe, where monthly costs run $83–$144 compared to the $800–$1,300 range still common in parts of the U.S. market.[3]
Racial disparities, independent of insurance status
Obesity disproportionately affects Black and Hispanic Americans, with prevalence rates of 53% and 43% respectively, compared to the overall adult rate above 40%.[4] The disparity compounds rather than resolves at the treatment level: Black adults experience significantly less weight loss from behavioral interventions than white adults, and lower-income individuals generally have less access to structured behavioral programs in the first place — meaning the population with the highest need has historically had the least effective access to the non-pharmacological alternative, independent of whatever medication access looks like.
The status quo — relying on lifestyle modifications — has actually expanded existing health disparities.
Age-specific disparities: the adolescent data
A retrospective cohort analysis of GLP-1RA prescribing among more than 2 million U.S. adolescents with obesity found that, after adjustment for clinical factors, several groups were significantly less likely to receive a prescription: male adolescents, Hispanic/Latino and non-Hispanic Black adolescents, those in socioeconomically disadvantaged or rural areas, and patients insured by Medicaid.[5] The study's authors specifically noted that Medicaid-covered youth were prescribed at markedly lower rates in their denominator-based analysis, despite earlier dispensing-only analyses suggesting Medicaid beneficiaries represented a large share of adolescent GLP-1 users — a divergence the authors attribute to insurance coverage restrictions and prior authorization requirements shaping who actually completes the prescribing process.
Why "large share of users" and "low prescribing rate" can both be true
If Medicaid covers a large population of adolescents with obesity overall, that population can still represent a large raw number of prescriptions while having a lower prescribing rate than commercially insured adolescents — a distinction between numerator-only and denominator-based analysis that changes the equity conclusion substantially. This is a useful general lesson for interpreting access disparities claims: always check whether a statistic is measuring share of total users or rate within an eligible population.
Adherence as a hidden equity dimension
Persistence data adds another layer: even among patients who do access treatment, adherence varies, and cost-related discontinuation likely falls disproportionately on patients with less financial cushion to absorb high-deductible cost-sharing or coverage gaps during dose titration — though registry data on adherence specifically stratified by socioeconomic status remains limited as of this writing.
Policy responses underway
The CMS BALANCE model, announced December 2025, is a five-year Innovation Center model intended to expand obesity drug access in Medicaid through standardized coverage criteria and lifestyle supports. It is voluntary for participating states, Medicare Part D plans, and manufacturers, with a target start of May 2026 for the Medicaid component and January 2027 for Medicare Part D.[6]
The Medicare GLP-1 Bridge demonstration, covered separately on this site, launched July 1, 2026 as a shorter-term precursor specifically for Medicare Part D beneficiaries, ahead of the BALANCE model's full 2027 Part D implementation.
Economic modeling from USC's Schaeffer Center estimates broad Medicare access to GLP-1s could generate $175–245 billion in savings over the first 10 years, with roughly 60% coming from reduced hospitalizations and nursing home care, and projects annual investment returns exceeding 13% after accounting for treatment costs.[7] Whether that projected return materializes depends substantially on the adherence and access patterns documented throughout this literature — a population that can't afford to start or stay on treatment can't generate the downstream health savings the model assumes.
Compare GLP-1 telehealth providers
Source GLP-1 tracks pricing, licensing, and provider structure across the market.